Chundsell Medicals AB
A new era for selecting the most optimal Prostate Cancer Treatment
The Prostatype® Test System can, by measuring gene expression levels and combining the result with other clinical parameters, give a more accurate prognosis for prostate cancer patients. This will open up for more personalised treatment options and potentially give a better quality of life for prostate cancer patients and their relatives.
Prostate cancer, one of the most common cancers worldwide
Today, more than 400 000 men are diagnosed with prostate cancer in the European countries and it is currently one of the most common cancers worldwide. In Sweden, there are approximately 10 000 men diagnosed with prostate cancer each year and the majority will receive aggressive treatment such as radical prostatectomy, radiation and chemotherapy. Even though radical treatment can be efficient in terms of eradicating any future risk of prostate cancer, side effects such as incontinence and erectile dysfunction can severely affect their quality of life and should only be performed when it is necessary. During the last 45 years the mortality of prostate cancer patients in Sweden has remained steady with approximately 2 400 deaths per year whereas the incidence has increased tenfold which is a result from new diagnostic routines.
Commercialisation of important research results from the Karolinska Institute
Chundsell Medicals AB was founded in 2007 as a spin off from the Karolinska Institute in Solna, in order to commercialize research results from Chunde Li and his research group on prostate cancer genomics. The first product: The Prostatype® Test System can assess prostate cancer aggressiveness in conjunction with currently used clinical parameters. The Prostatype®Test System consist of an RT-qPCR kit and a unique software with a database filled with authentic but anonymous patient cases. The Prostatype RT-qPCR kit measures the expression levels of three selected and specific biomarker genes in prostate cancer tissue specimens. The result from these expression patterns together with currently used clinical parameters such as prostate specific antigen (PSA), Gleason score, age etc. will be utilized with the stand-alone software, the Classification of Prostatic Malignancy Algorithm (CPMA). The software will compare the data from the new patient with the authentic historical patient cases in the database and sort out the patient cases with most similar profiles as the new patient. By displaying the treatment programs and overall survival from the historical patient cases, it will be possible for the healthcare professionals to predict the disease outcome with a higher precision than before. This means that potentially more personalised treatment programs can be applied for each and every patient.
Beneficial for both patients and the society
We believe that the Prostatype® Test System will provide an additional prognostic statement that will guide the healthcare professionals to make more precise decisions in terms of prostate cancer prognosis and treatment programs, and as a consequence substantially reduce the number of patients treated with radical methods. In addition, the use of the Prostatype® Test System will have beneficial effects not only for prostate cancer patients but also from a economical point of view. The estimated yearly cost for surgery, radiation and rehabilitation is approximately 220 000 SEK per prostate cancer patient and year. However, hospitals using the Prostatype® Test System will be able to provide the healthcare professionals with more accurate information and thereby simplifying the choice of the most suitable treatment for every patient.
Our goal – to increase Quality of Life
Our mission at Chundsell Medicals is to improve the quality of life for patients diagnosed with prostate cancer and their relatives. The Prostatype® Test System will meet an urgent medical need and provide life-saving information while reducing healthcare costs and preserving the quality of life for thousands of men each year.